These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1007279)

  • 21. BCG immunotherapy in previously treated malignant melanoma patients.
    Mujagić H; Kolarić K; Malenica B; Nola P
    Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
    Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
    Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological monitoring of melanoma patients on BCG immunotherapy. I. Enzyme-linked immunosorbent assay of human sera after BCG-treatment.
    Kovatchev D; Kolushky V; Engibarov A
    Neoplasma; 1984; 31(4):453-8. PubMed ID: 6472516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Basis for a specific-active immunotherapy in malignant melanoma].
    Mutzner PA; Stuhlmiller GM; Seigler HF; Stumpf WE; Sar M
    Schweiz Med Wochenschr; 1981 Sep; 111(36):1322-5. PubMed ID: 7302537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
    Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
    Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonspecific antigen reactions.
    Klein E; Rosner D; Holtermann OA; Stoll HL; Song SY
    Natl Cancer Inst Monogr; 1976 Nov; 44():87-97. PubMed ID: 799764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-directed immune reactivity and immunotherapy in malignant melanoma. Current status.
    Mavligit G; Gutterman JU; McBride C; Hersh EM
    Prog Exp Tumor Res; 1974; 19():222-52. PubMed ID: 4612607
    [No Abstract]   [Full Text] [Related]  

  • 28. A technique for intensifying BCG sensitivity.
    Parmett SR; Klein E
    J Med; 1975; 6(3-4):213-6. PubMed ID: 1104733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Local immunotherapy. Alternative therapy for malignant cutaneous lesions (demonstration on 30 patients with malignant melanoma) (author's transl)].
    Kokoschka EM; Micksche M
    Wien Klin Wochenschr; 1979 Mar; 91(5):150-4. PubMed ID: 425533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
    Thatcher N; Crowther D
    Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Development in the immunotherapy of malignant melanoma].
    Tritsch H
    Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides.
    Ueda Y; Shimizu K; Itoh T; Fuji N; Naito K; Shiozaki A; Yamamoto Y; Shimizu T; Iwamoto A; Tamai H; Yamagishi H
    Jpn J Clin Oncol; 2007 Feb; 37(2):140-5. PubMed ID: 17255158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunologic evaluation of patients with cancer by delayed hypersensitivity reactions.
    Burdick JF; Wells SA; Herberman RB
    Surg Gynecol Obstet; 1975 Nov; 141(5):779-94. PubMed ID: 128144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
    Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
    Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study.
    Galligioni E; Quaia M; Merlo A; Carbone A; Spada A; Favaro D; Santarosa M; Sacco C; Talamini R
    Cancer; 1996 Jun; 77(12):2560-6. PubMed ID: 8640706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunology and therapy of malignant melanoma (author's transl)].
    Kokoschka EM; Micksche M
    Wien Klin Wochenschr; 1977 Sep; 89(18):612-22. PubMed ID: 906525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCG in cancer therapy: theoretical bases of immunotherapy.
    Dodd MJ
    Am J Nurs; 1979 Feb; 79(2):310-4. PubMed ID: 311587
    [No Abstract]   [Full Text] [Related]  

  • 38. Purification of soluble human melanoma-associated antigens.
    Roth JA; Slocum HK; Pellegrino MA; Holmes EC; Reisfeld RA
    Cancer Res; 1976 Jul; 36(7 PT 1):2360-4. PubMed ID: 776393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Demonstration of lymphocyte blastogenesis--inhibiting factors in sera of melanoma patients.
    Rangel DM; Golub SH; Morton DL
    Surgery; 1977 Aug; 82(2):224-32. PubMed ID: 877866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Some aspects of cell-mediated hypersensitivity in patients with melanoma.
    Moszkowska G; Jassem J; Kondrat W; Kopacz A; Goszczyńska E
    Arch Immunol Ther Exp (Warsz); 1980; 28(4):655-60. PubMed ID: 6970028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.